The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)

Ombretta Annibali, Stefan Hohaus, Francesco Marchesi, Maria Cantonetti, Alice Di Rocco, Valeria Tomarchio, Arianna Di Napoli, Sabrina Pelliccia, Roberta Battistini, Paola Anticoli Borza, Elisabetta Abruzzese, Natalia Cenfra, Alessandro Andriani, Cristiano Tesei, Eleonora Alma, Francesca Palombi, Livio Pupo, Luigi Petrucci, Marco Becilli, Elena MaioloSilvia Bellesi, Annarosa Cuccaro, Francesco D’Alò, Maria Christina Cox

Research output: Contribution to journalArticlepeer-review

Abstract

In solid tumors and lymphomas, the neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor. The aim of our study was to validate the originally reported N/L ratio cut-point of 3.5 in patients with diffuse large B-cell lymphoma (DLBCL) registered in an Italian real-life database. The prognostic role of the N/L ratio at diagnosis on event-free survival (EFS) and overall survival (OS) was assessed in 505 patients with DLBCL. Patients with an N/L ratio <3.5 (n = 249) had a 4-year EFS probability of 76% and OS probability of 86%, significantly higher than the 4 year EFS rate of 48% and OS rate of 64% in patients with N/L ratio ≥3.5 (n = 256, both p<.0001). The N/L ratio was an independent prognostic factor in the multivariate analysis including the IPI score, and could separate patients with a low/intermediate risk IPI (IPI <3).

Original languageEnglish
Pages (from-to)3386-3394
Number of pages9
JournalLeukemia and Lymphoma
Volume60
Issue number14
DOIs
Publication statusPublished - Dec 6 2019

Keywords

  • cancer
  • DLBCL
  • lymphoma
  • N/L ratio
  • R-CHOP

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI)'. Together they form a unique fingerprint.

Cite this